PT  - JOURNAL ARTICLE
AU  - Eva Ailín Vallejos
AU  - Sabrina Resnik
AU  - Florencia Santtia
AU  - Laura Barria
AU  - Federico Felder
AU  - Mariano Sosa
AU  - Facundo Nogueira
AU  - Juan Enghelmayer
AU  - Ana Putruele
AU  - Carlos Luna
TI  - COVID-19 pneumonia and clinical follow-up: results of a prospective cohort
AID  - 10.1183/13993003.congress-2021.PA3650
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3650
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3650.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3650.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: COVID-19 pandemic has led to a rise in hospitalized patients with viral pneumonia and we are still learning about the follow-up process.Objective: To describe a cohort of hospitalized patients with COVID pneumonia and the clinical follow up once discharged.Methods: Prospective cohort study. COVID pneumonia patients from August 2020 to January 2021 were analyzed (n=72), with a standardized clinical follow-up a month after discharge. We describe clinical features, extent of pneumonia and treatment provided. We define Extent Pneumonia as an affection of ≥ 4 of 6 radiographic zones and/or 3 of 5 lobes in chest CT and compare vs Non extent pneumonia. Lastly, we describe the findings on the clinical follow-up.Results: Table 1: Cohort´s description. Table 2: Extent and Non extent pneumonia comparison. Clinical follow-up: 8(11.1%) patients persist symptomatic after discharge (4cough-3dyspnea-1anosmia). Age(yrs)59(46-72)Male(%)37(51.4)Chronic Lung Disease, total(%)Former/Actual SmokerCOPDAsthma36(50)24(33.3)5(6.9)2(2.8)Hypertension(%)26(36.1)Diabetes(%)13(18.1)Immunosuppresion(%)11(15.3)FeverCoughDyspnea56(77.8)42(58.3)40(55.6)O2 required(%)48(66.7)COVID treatment(%)Convalescent plasma + SteroidsSteroids51(70.8)37(51.4)14(19.4)Non-Extent pneumoniaExtent pneumoniap valueImmunosuppression(%)0(0)11(20.4)0.037Fever(%)9(12.5)47(65.3)0.001Dyspnea(%)6(8.3)34(47.2)0.028O2 required(%)7(9.7)41(56.9)0.004Symptom persistence2(2.8)6(8.33)0.001Conclusions: We present a thorough description of clinical data and our findings define the features associated with extent pneumonia. The clinical follow-up showed a relatively low frequency of symptom persistence.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3650.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).